SOUTH SAN FRANCISCO, Calif.,
Jan. 6, 2020 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused
precision medicine company committed to the discovery and
development of targeted therapeutics to treat cancer, announced
that the company is scheduled to present at the 38th
Annual J.P. Morgan Healthcare Conference in San
Francisco on Wednesday, January 15, 2020 at 5:00
p.m. PT (8:00 p.m. ET).
___________________
About IDEAYA Biosciences
IDEAYA is an oncology-focused
precision medicine company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with small molecule drug discovery to select patient
populations most likely to benefit from the targeted therapies
IDEAYA is developing. IDEAYA is applying these capabilities
across multiple classes of precision medicine, including direct
targeting of oncogenic pathways and synthetic lethality – which
represents an emerging class of precision medicine
targets.
__________________
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to expected presentation of company information
and timing therof at the J.P. Morgan Healthcare Conference.
Such forward-looking statements involve substantial risks and
uncertainties that could cause IDEAYA's preclinical and clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including IDEAYA's programs' early stage of development,
the process of designing and conducting preclinical and clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, IDEAYA's ability to successfully establish, protect and
defend its intellectual property and other matters that could
affect the sufficiency of existing cash to fund operations. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Quarterly Report on Form 10-Q filed on November 13, 2019 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
___________________
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-on-wednesday-january-15-2020-300980719.html
SOURCE IDEAYA Biosciences, Inc.